瑞舒伐他汀钙用药剂量对稳定型心绞痛合并心衰的疗效观察

Effect of Different Doses of Rosuvastatin Calcium on StableAngina Pectoris Combined with Heart Failure

目的:观察瑞舒伐他汀钙用药剂量对于稳定型心绞痛合并慢性心力衰竭患者的治疗效果。方法:选取本院2015年1月~2019年1月间本院收治的228例稳定型心绞痛(SAP)合并慢性心力衰竭(CHF)患者纳入本次研究,将入选患者随机均分后,分别纳入低量组与高量组(n=114),两组患者均应用瑞舒伐他汀钙治疗,低量组给予10 mg/d,高量组给予20 mg/d;治疗一疗程(6个月)后,评估两组临床疗效,观察两组患者治疗前后心功能、血脂水平,统计治疗期间两组患者的不良反应发生率。结果:高量组总有效率为92.98%,低量组为77.19%,高量组临床疗效优于低量组,差异有统计学意义(P<0.05);治疗后,两组患者心功能、血脂水平、FMD均较本组治疗前改善,且高量组均优于低量组,差异均有统计学意义(P<0.05);低量组不良反应发生率为5.26%,高量组为8.77%,两组不良反应发生率差异无统计学意义(P>0.05)。结论:高剂量瑞舒伐他汀钙对稳定型心绞痛合并心衰疗效更为理想,且用药剂量安全可行。

Objective:To observe the therapeutic effect of rosuvastatin calcium on patients with stable angina combined with chronic heart failure.Methods:228 patients with stable angina pectoris(SAP)combined with chronic heart failure(CHF)admitted to our hospital from January 2015 to January 2019 were included int the current study and randomly divided into two groups,the low volume and high volume groups.Both groups of patients were prescribed with rosuvastatin calcium,low volume group with 10 mg/d,high volume group with 20 mg/d.After one course of treatment(6 months),the clinical efficacy,the changes of cardiac function,lipid level before and after treatment,the incidence of adverse reactions were evaluated.Results:The total effective rate of the high-dose group was 92.98%,and that of the low-dose group was 77.19%(P<0.05).After treatment,the cardiac function,lipid level in both groups was improved,with more changed observed in the high volume group(P<0.05).The incidence of adverse reactions was 5.26%in the low-dose group and 8.77%in the high-dose group(P>0.05).Conclusion:High dose rosuvastatin calcium showed better treatment effects on patients with stable angina pectoris complicated with heart failure,and the applied dosage is safe and feasible.